

IMPACT OF VERTEBRAL FRACTURE ON AUXOLOGICAL PROFILE AND INSULIN-LIKE GROWTH FACTORS OF CHILDREN AFTER ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT

M. AHN, S. KIM, N LEE, S. KIM, W. CHO, K. CHO, M. JUNG, BK. SUH

Department of Paediatrics, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea



INTRODUCTION

Children with acute lymphoblastic leukemia (ALL) often experience diverse skeletal complications following the treatment. Vertebral fracture (VF) is the hallmark of osteoporosis and have been recognized as a major skeletal complication of ALL. VF are frequently asymptomatic, thereby undetected in the absence of routine surveillance and its severity is related to the height decline^{1, 2)}. Insulin-like growth factor-1 (IGF-1) is a critical mediator of bone growth while its concentration is lower in osteoporotic patients³⁾.

AIM

This study aimed to investigate the overall prevalence of VF following childhood ALL treatment and examine the height trajectory and insulin-like growth factors in association with the presence of VF.

RESULTS

Mean age at ALL diagnosis was 6.5±3.4 years with treatment duration of 4.0±1.8 years (Table 1). Mean height and body mass index Z-score of study subjects at baseline was -0.1 ± 1.0 and 0.3 ± 1.4 . respectively. Thirty-five children (20.3 %) had VF at baseline, and among those with VF, 97.1 % had either mild or moderate deformity. 5th lumbar vertebrae was the most frequently injured site (20.0 %). Median lumbar spine bone mineral density *Z*-score was -1.0 (Interquartile range of -1.6 and -0.8) in children with VF. Baseline Z-scores for height and weight were lower in children with VF than without VF while height Z-scores in children with VF had greater height decline than without VF (0.5±0.6 and 0.2±0.8; *P*=0.02) (**Figure 1**). Children with VF had lower IGF-1 and IGFBP-3 Z-scores than without VF at TC (**Table 2**). Decrease in IGF-1 level was associated with the presence of VF (Table 3).

Clinical Parameters	Results(n=172)
Demographic data	
Age	
Baseline, y	10.3±3.4
At ALL diagnosis, y	6.3±3.4
Male, n (%)	102 (59.3)
Leukemia characteristics	
Classification	
Pre-B-cell	164 (95.3)
T-cell	7 (4.1)
Biphenotype	1 (0.6)
Treatment	
Duration, y	4.0±1.8
Chemotherapy only (%)	139 (80.8)
Chemotherapy + Transplantation (%)	33 (19.2)
Anthropometry	
Height Z-score	-0.1±1.0
Weight Z-score	0.2±1.2
BMI Z-score	0.3 ± 1.4
VF assessment	
VF, n (%)	35 (20.3)
Mild or moderate deformity, n (%)	24 (97.1)
Most frequent location, vertebra (%)	L5 (20.0)
DEXA, n (%)	19 (9.1)
LSBMD Z-score, median (IQR)	-1.0 (-1.6, -0.8)

 Table 1. Description of the Cohort at Baseline

-1.2±1.0 -2.3±1.1	0.0±0.8 -1.3±1.0	<0.01 <0.01
-2.3±1.1	-1.3±1.0	<0.01
-1.2±0.9	-0.3±0.8	<0.01
-1.6±0.9	-0.9±0.9	<0.01

Table 2. Comparison of IGF-1 and IGFBP-3 in Children With and Without VF




Figure 1. Height Z-scores of Children with VF from Pre- to Post-treatment

	OR (95 % CI)	P
At TC		
Height Z-score	0.7 (0.4-1.4)	0.37
IGF-1 Z-score	0.3 (0.2-0.5)	<0.01
IGFBP-3 Z-score	0.7 (0.4-1.1)	0.12

Table 3. Association of IGF-1 and IGFBP-3 with the Presence of VF

METHOD

One hundred and seventy-two children (59.3 %, male) who were diagnosed with ALL at age between 2 and 18 years visited endocrinology clinic following the treatment completion (baseline) were screened for lateral thoracolumbar spine radiographs for VF detection (interpretation by using semiquantitative method)3). Anthropometric measurements were obtained at three time points: at leukemia diagnosis (LD), treatment completion (TC), and 12 months after TC. The association of IGF-1 and insulin-like growth factor binding protein-3 (IGFBP-3) with the presence of VF were examined.

CONCLUSIONS

Substantial number of children encountered VF once ALL treatment was completed and the presence of VF might lead to compromised auxological state, prominent height decline and IGF-1 deficiency. Routine VF surveillance at pre- and post-treatment, is critical for the prevention of future VF incidence.

REFERENCES

- 1 Cumming EA et al. Incident Vertebral Fractures in Children With Leukemia During the Four Years Following Diagnosis. J Clin Endocrinol Metab 2015; 100(9): 34089-17
- 2 Ma J et al. Impact of Vertebral Fractures and Glucocorticoid Exposure on Height Deficits in Children During Treatment of Leukemia. J Clin Endocrinol Metab 2019; 104(2): 219-22
- 3 Locatelli V et al. Effect of GH/IGF-1 on Bone Metabolism and Osteoporosis. Int J Endocrinol 2014; doi.org/10.1155/2014/235060
- 4 Genant HK et al. Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1996; 11(7): 984-96

ACKNOWLEDGEMENTS

Not applicable

CONTACT INFORMATION

Moon Bae Ahn (mbahn@catholic.ac.kr)

